Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

HUYA: Untouched By Regulatory Headwinds

09:54am, Thursday, 23'rd Dec 2021 Seeking Alpha

HUYA: Untouched By Regulatory Headwinds

04:54am, Thursday, 23'rd Dec 2021
HUYA is a leader in the gaming streaming industry in China. After their planned DouYu merger fell through, I provide a fresh look at their independent organic growth potential.

HUYA (NYSE:HUYA) Shares Gap Down to $7.35

04:04pm, Wednesday, 22'nd Dec 2021 Dakota Financial News
Shares of HUYA Inc. (NYSE:HUYA) gapped down prior to trading on Wednesday . The stock had previously closed at $7.35, but opened at $7.16. HUYA shares last traded at $7.07, with a volume of 15,528 shares. Several analysts have recently issued reports on the company. Zacks Investment Research upgraded HUYA from a sell rating to []

HUYA (NYSE:HUYA) Shares Up 9%

05:44pm, Tuesday, 21'st Dec 2021 Dakota Financial News
HUYA Inc. (NYSE:HUYA) shot up 9% on Tuesday . The company traded as high as $7.38 and last traded at $7.38. 62,494 shares changed hands during trading, a decline of 98% from the average session volume of 3,095,807 shares. The stock had previously closed at $6.77. A number of brokerages recently weighed in on HUYA. []
The trading price of HUYA Inc. (NYSE:HUYA) closed lower on Monday, December 13, closing at $7.48, -2.09% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
Parametric Portfolio Associates LLC boosted its holdings in HUYA Inc. (NYSE:HUYA) by 170.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 135,201 shares of the companys stock after buying an additional 85,217 shares during the quarter. Parametric Portfolio Associates []
HUYA Inc. (NYSE:HUYA) price on Friday, December 10, fall -0.13% below its previous days close as a downside momentum from buyers pushed the stocks value to $7.43. A look at the stocks price movement, the level at last check in todays session was $7.44, moving within a range at $7.43 and $7.90. The beta value Thinking Of Selling HUYA Inc. (NYSE: HUYA) Shares? You Need To Know This Read More »

Analysts Say HUYA Inc. Can Reach $147.29 In 12 Months

03:00pm, Friday, 10'th Dec 2021 Marketing Sentinel
HUYA Inc. (NYSE:HUYA)s traded shares stood at 2.13 million during the last session, with the companys beta value hitting 0.79. At the close of trading, the stocks price was $7.44, to imply a decrease of -5.94% or -$0.47 in intraday trading. The HUYA shares 52-week high remains $36.33, putting it -388.31% down since that peak Analysts Say HUYA Inc. Can Reach $147.29 In 12 Months Read More »

HUYA (NYSE:HUYA) Upgraded to Hold at Zacks Investment Research

06:16am, Thursday, 09'th Dec 2021 Transcript Daily
HUYA (NYSE:HUYA) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Tuesday, Zacks.com reports. According to Zacks, HUYA Inc. provides online services. The Company offers interactive video broadcast service which includes e-sports, music, reality show and more. HUYA Inc.is based in Guangzhou, []

Royal Bank of Canada Boosts Stake in HUYA Inc. (NYSE:HUYA)

09:22am, Wednesday, 08'th Dec 2021 Transcript Daily
Royal Bank of Canada increased its stake in HUYA Inc. (NYSE:HUYA) by 704.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,850 shares of the companys stock after purchasing an additional 22,638 shares during the quarter. Royal Bank of Canadas holdings in HUYA were []

Financial Analysis: Moxian (NASDAQ:MOXC) & HUYA (NYSE:HUYA)

08:34am, Monday, 06'th Dec 2021 Dakota Financial News
Moxian (NASDAQ:MOXC) and HUYA (NYSE:HUYA) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership. Insider & Institutional Ownership 14.7% of Moxian shares are owned by institutional investors. Comparatively, 78.0% of []

Baillie Gifford & Co. Has $63.66 Million Stake in HUYA Inc. (NYSE:HUYA)

01:02pm, Saturday, 04'th Dec 2021 Dakota Financial News
Baillie Gifford & Co. decreased its holdings in shares of HUYA Inc. (NYSE:HUYA) by 17.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,632,744 shares of the companys stock after selling 1,600,164 shares during the quarter. Baillie Gifford & []

12-Month Price Target For HUYA Inc. (NYSE:HUYA) Now Sits At $147.29

05:00pm, Friday, 03'rd Dec 2021 Marketing Sentinel
In recent trading session, HUYA Inc. (NYSE:HUYA) saw 2.5 million shares changing hands at last check today with its beta currently measuring 0.79. Company’s recent per share price level of $6.36 trading at -$1.02 or -13.84% at last check today assigns it a market valuation of $1.76B. That most recent trading price of HUYA’s stock … 12-Month Price Target For HUYA Inc. (NYSE:HUYA) Now Sits At $147.29 Read More »

HUYA (NYSE:HUYA) Shares Up 4.6%

09:48am, Thursday, 02'nd Dec 2021 Transcript Daily
HUYA Inc. (NYSE:HUYA) shot up 4.6% on Tuesday . The company traded as high as $8.27 and last traded at $8.22. 48,096 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 2,304,372 shares. The stock had previously closed at $7.86. A number of brokerages have recently weighed in []
SHENZHEN, China , Dec. 1 , 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences'' licensing partner, HUYABIO International (HUYABIO), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan . "Relapsed and/or refractory PTCL carries a grim prognosis with limited treatment options. Data from the registration study of Chidamide has demonstrated meaningful disease response despite the advanced stage of disease, and acceptable safety profile, to address an important unmet medical need in this patient population", said Dr. Kensei Tobinai, Visiting Scientist of the National Cancer Center Hospital in Japan and medical expert of Chidamide Phase 2 study. The drug was approved based on data from a Phase 2b study that involved 55 patients with aggressive PTCL in Japan and Korea. These patients, having few effective treatment options, all had advanced disease either refractory to or relapsed to prior therapies.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE